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The European Paediatric Formulation Initiative (EuPFI, www.eupfi.org) with the APV 
(Arbeitsgemeinschaft für Pharmaceutische Verfahrenstechnik) hosted its 6th conference on 
“Formulating better medicines for children” on the 17-18th September 2014 in Athens, Greece. This 
meeting attracted 119 delegates with good representation from industry, regulatory agencies, 
academic and clinical settings.  
This meeting is now in its 6th year and offers a unique opportunity for paediatric formulation 
specialists to exchange and present recent accomplishments as well as discuss remaining challenges 
for the future with a vision of better medicines for children.  Although this is a European meeting, 
collaborations with the US have always been integral to the success of improving formulating 
paediatric medicines and bridging the adult-child medicines gap.  This meeting was no exception to 
this with a great presentation by Trupti Dixit on the United States of America based Innovation and 
Quality (IQ) Consortium survey. The survey focused on understanding the current status of pediatric 
formulation development in the US including common approaches used, limitations of those 
approaches, current regulatory expectations and unmet needs. Dr Jenny Walsh presented the 
European survey on paediatric medicine administration devices: experiences and opinions of 
healthcare professionals. 
Although this meeting is well established on the calendar of those interested in paediatric 
formulation there was an opportunity for those attending who are new to the area to get up to 
speed by attending the two pre-conference workshops. The workshops are held to provide much 
needed focus on paediatric clinical pharmacology and to introduce the regulatory framework/quality 
section of PIPs. These sessions were presented by Dr Janko Samardzic (University of Belgrade, 
Belgrade, Serbia) and Dr Siri Wang (Norwegian Medicines Agency, Oslo, Norway) respectively and 
allowed attendees to ask questions to build up knowledge and dialogue in these areas. Dr Janko 
Samardzic talked through the fundamental differences that mean that children are not just small 
adults and reflected on clinical knowledge in this area. Dr Wang highlighted many interesting aspects 
from PIPs submitted to date and reflected on the low numbers of PUMAs since the regulations were 
introduced in 2007. She noted that PUMA reflect product development funded through a series of 
projects where potentially a different source funds is required at each step and therefore it may be 
anticipated that these will be slower compared to PIPs to reach the market. As a smaller, more 
engaged and focused conference, the pre-conference workshops offered an opportune setting to 
meet and connect with many friends and colleagues working in this field, and provided an effective 
learning platform given the wide array of presentations on offer. 
The programme for the EuPFI meeting is participant driven and is typically designed around the 
challenges faced in developing paediatric medicines, which in turn are also the workstreams that 
comprise the EuPFI activity (http://www.eupfi.org/gpage2.html) 
 Pharmaceutical Excipients 
 Taste masking and taste assessment methods 
 Administration devices 
 Age appropriate formulations  
 Modification of Dosage Forms Required for Children 
 Biopharmaceutics (NEW) 
Talks were related to these workstreams or presented as the result of ongoing activity lead from 
within the workstreams. As with previous years any feedback is included into future programmes to 
ensure that the meeting meets the needs and expectations of the attendees. 
A main emphasis of the meeting was reflecting on the updated EMA Guideline on pharmaceutical 
development of medicines for paediatric use, which came into effect in February 2014.  It was 
acknowledged by all parties that although these guidelines are required, the evidence base is not 
sufficiently robust and further work is required to underpin aspects of this guidance. However, it was 
recognised that paediatric formulation development is leading the way for other special populations 
and this year the alignment of formulation development for paediatric and geriatric populations was 
the subject of two stimulating presentations (industry and academia). 
Both Europe and the United States of America have dedicated networks that collaborate to improve 
medicines for children, however, this issue is global. It is essential that age-appropriate medicines 
are available for all children who require them. Sonja Skopp (Merck KGaA, Darmstadt, Germany) 
presented a paediatric schistosomiasis treatment; an innovation to play a more direct role in the 
fight against the second-most severe tropical disease in Africa. The current gold standard treatment 
of schistosomiasis employs annual single oral dose of the drug praziquantel (PZQ) 600 mg tablets. 
The available formulation of praziquantel (PZQ) is not suitable for paediatric use and cannot be 
readily administered to children especially to preschool-age children and infants. In order to tackle 
this important public health problem, a consortium was formed in July 2012 under the leadership of 
Merck KGaA with the goal of developing a suitable paediatric praziquantel formulation appropriate 
for children from the age of 3 months to 6 years and register its use in schistosomiasis.  
Norbert Poellinger (Glatt GmbH, Germany) presented the TAIN project, treatment of adrenal 
insufficiency in neonates and infants (www.tain-project.org/). The off-patent drug hydrocortisone is 
a glucocorticoid hormone that has been used as a replacement therapy for the treatment of Adrenal 
Insufficiency across Europe for many years. However, effective hydrocortisone replacement is 
particularly acute among young patients (neonates and infants) for whom no licensed therapy exists. 
The aim of TAIN is to develop a new formulation of hydrocortisone – Infacort® - that can be used 
from birth and specifically in the age range 0 – 2 years. It also aims to raise awareness of the unmet 
needs in paediatric adrenal insufficiency patients. 
Shorts talks (soapbox sessions) from submitted abstracts, innovation showcases and 50 posters were 
also presented at the meeting all of which provided opportunities for networking and the initiation 
of new collaborations.  
The soapbox sessions included a wide range of topics and highlighted the diversity of research within 
the umbrella of paediatric formulations. Particular highlights included a talk from Jennifer Bellis 
(Alder Hey Children’s NHS Foundation Trust, Liverpool, UK) on the frequency and type of unlicensed 
medicines implicated in adverse drug reactions (ADRs) in paediatric inpatients; the results showed 
that unlicensed medicines were more than twice as likely to be implicated in an ADR as authorised 
medicines. Ramona Trastullo (University of Bologna, Bologna, Italy) presented on the development 
of fast dissolving granules containing praziquantel as a formulation that is likely to improve 
acceptability compared to the current tablets used in children. A continuous manufacturing process 
that produces double-layer orodispersible films as a paediatric formulation was described by Yasmin 
Thabat (Heinrich-Heine-University, Dusseldorf, Germany); this formulation has advantages in the 
manufacture of combination therapeutics. Annette Grave (Glatt GmbH, Germany) shared results 
where the extremely bitter drug, hydrocortisone was successfully taste masked within a micropellet 
whilst maintaining an immediate release dissolution profile. This production of taste-masked 
micropellets was also successfully scaled up to the production scale providing a product that allows a 
flexible capsule filling over a wide range of a range of strengths for adaptive dosing  
Poster prizes were awarded for the three best posters presented at the meeting. These awards were 
kindly sponsored by PCCA (Professional Compounding Centers of America) and were presented to  
Jessica Soto from UCL School of Pharmacy for the presentation “Assessing the taste of medicines 
with rodents: the in vivo rat brief-access taste aversion (BATA) model”; Jonas Buck for “Development 
and characterization of dispersible tablets employing novel characterization methods” and joint 
award to Saskia Blank and Elizabeth Kersten from  University of Greifswald, Germany for  
“Monitoring food and fluid intake as a basis for establishing biorelevant dissolution methods for 
children in the age of 1 – 6 years” Conference proceedings are available at 
http://eupfi.org/Conference%202014/default.htm 
The innovation showcase provided an opportunity for businesses working in paediatric formulations 
to raise the profile of their technology and share potential applications. The X-Straw dose sipping 
technology was presented by Elke Sternberger-Rützel (DS Technology, Harro Höfliger, Germany) this 
is a prefilled straw with an exact dose that is delivered upon drinking. Mauro Serratoni (Aptalis 
Pharma, Italy) highlighted patient centered paediatric drug formulation options using MicroCAPS® 
taste masking technology in combination with AdvaTab® to create an immediate release orally 
disintegrating tablet of a bitter tasting drug. The RauDoseTM technology was introduced by Gero 
Eichelkraut (Raumedic AG, Germany); this device provides a means of measuring precise and safe 
doses of liquid medicines. 
The “rapid communications” summarizing the oral presentations that took place over the 2 days are 
presented in this special issue 
1. Workshop 1: Introduction to developmental pharmacology  
 
2. Workshop 2: Introduction to regulatory framework / quality section of PIPs 
 
3. Drug dosage forms and food mixing  
 
4. Milk as a medium for paediatric formulations: experimental findings and regulatory aspects  
 
5. Quality considerations of PIPs for monoclonal antibodies: a regulatory perspective 
 
6. Formulation factors affecting acceptability of medicines in children and older adults   
 
 
In addition, 2 presentations were selected for full length manuscripts: 
1. European survey on paediatric medicine administration devices: experiences and opinions of 
healthcare professionals  
  
2. Usability testing – STEP database through end-users eyes 
  
The other presentations that are not part of the IJP issue include cell-based assays for taste 
prediction by Dr Afzal Mohamed.  The data about cell lines that respond to taste stimuli and are 
likely to have value in the in vitro assessment of the taste of paediatric medicines was shared. A 
spinout workstream of age appropriateness of formulation has been introduced   this year and Prof 
Sandra Klein (University of Greifswald, Germany) presented on the biopharmaceutical evaluation of 
developmental paediatric products. An overview on the limitations of existing methodologies in this 
field and how researchers are addressing this to better predict the in vivo performance of paediatric 
oral medicines was presented. 
This meeting was a success that embodied the EuPFI’s mission to share expertise and interactive 
discussion between industry, academia, clinical and regulatory professionals to promote and 
facilitate preparation of better & safe medicines for children. The participant list demonstrated that 
this topic was of interest to people with a wide range of background and questions or expectations, 
creating stimulating and rich discussions among attendees. This diversity is reflected by the articles 
published in this special issue of the International Journal of Pharmaceutics Sciences written by 
invited speakers.  
The issues and challenges associated with development of paediatric formulation were identified 
together with collaborative approaches to solving these issues as a result of the networking aspect 
of the meeting. This makes this the premier meeting on paediatric formulation. The willingness of 
participants to meet again resulted in the 8th meeting of EuPFI being scheduled for the 16-17th 
September 2015 in Antwerp, Belgium. We hope to see you there!   
 
